Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DT2216 + S63845 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DT2216 | DT 2216|DT-2216|PROTAC Bcl-XL Deagrader DT2216 | BCL-XL inhibitor 14 | DT2216 is a small molecule proteolysis-targeted chimera (PROTAC) that binds to BCL-XL and targets it for degradation, potentially resulting in decreased tumor growth (PMID: 31792461, PMID: 32677976). | |
S63845 | MIK655|MIK-655|MIK 655|S-63845|S 63845 | MCL1 Inhibitor 18 | S63845 (MIK655) is a small molecule drug that binds to and inhibits Mcl1, leading to apoptosis in tumor cells (PMID: 27760111, PMID: 32513939). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|